|
Delayed Onset Malignant Hyperthermia after SevofluraneDOI: 10.1155/2013/712710 Abstract: Malignant hyperthermia is a hypermetabolic response to inhalation agents (such as halothane, sevoflurane, and desflurane), succinylcholine, vigorous exercise, and heat. Reactions develop more frequently in males than females (2?:?1). The classical signs of malignant hyperthermia are hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, muscle rigidity and rhabdomyolysis. In this case report, we present a case of delayed onset malignant hyperthermia-like reaction after the second exposure to sevoflurane. 1. Introduction Malignant hyperthermia is characterized by a hypermetabolic response to triggering agents. In this case report, we present delayed onset malignant hyperthermia-like reaction after the second exposure to sevoflurane [1]. 2. Case An 8-day-old boy was scheduled for choanal atresia evaluation under general anesthesia. Anesthesia induction maintenance was done with sevoflurane 7-8%, after intubation remifentanil 2?μg was given. No muscle relaxant was used. Anesthesia lasted 35 minutes without any problem. One week after this procedure, the patient was scheduled for bilateral nasopharyngeal tube application under general anesthesia with sevoflurane. The procedure ended without any problem. During his followup, the temperature increased to 42.5°C, heart rate increased to 250/min, and respiratory distress developed. Creatinine phosphokinase levels reached 929?IU/L, and hyperpotassemia developed. Blood gas analysis revealed hypoxemia (SO2 < 85%), respiratory acidosis (PaCO2 > 60?mm?Hg) and metabolic acidosis (base deficit > 10?mEq/L). The clinical condition of the patient was thought to be due to malignant hyperthermia, and dantrolene sodium was given orally. After dantrolen sodium, the body temperature minimally decreased, and as the respiratory distress continued, the patient was intubated and mechanical ventilation was started. Dantrolen sodium 2.5?mg/kg was given intravenously with 6-hours intervals for 2 days and his temperature decreased. Following 10-hours period of intubation, the patient was extubated and CPAP was done. There was no family history of malignant hyperthermia or disease increasing the susceptibility to malignant hyperthermia in this patient. He was born with cesarean section after 39 weeks of gestation and his birth weight was 4050 and APGAR score was 6/8. Any systemic problems and fetal anomalies were not seen during pregnancy. There were 3 abortuses with unknown etiologies before this pregnancy. After the delivery as the baby had syndromic facial appearance and
|